Alligator Bioscience AB (FRA:7AL0) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 28, 2026)

Name: Alligator Bioscience AB (7AL0) — Historical Annual & Quarterly Data
Creator: GuruFocus
License: https://www.gurufocus.com/terms-of-service.php

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

What is Alligator Bioscience AB Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Alligator Bioscience AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Alligator Bioscience AB Margin of Safety % (DCF Dividends Based) Related Terms

FRA:7AL0 vs VRTX, REGN, RVMD: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alligator Bioscience AB Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Margin of Safety % (DCF Dividends Based) falls into.

Save Embed

Alligator Bioscience AB Business Description

Industry Healthcare Biotechnology

Comparable Companies XSAT:DBP B OSTO:GUARD XSAT:RESP OSTO:MAGLE XSAT:PHAL XSAT:APTA OSTO:FLUI OSTO:NANECH OSTO:BIOSGN OSTO:EXPRS2 VRTX REGN XBRU:ARGX XBRU:UCB XKRX:207940 RVMD ASX:CSL ALNY ONC XKRX:068270

Other Exchanges ATORX:Sweden 0RK9:UK

Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website https://www.alligatorbioscience.se

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.